Post-Marketing Surveillance of Prazaxa® on the Long-term Use in Patients With Nonvalvular Atrial Fibrillation

Boehringer Ingelheim

Status: Completed

Conditions: Atrial Fibrillation

Treatments: Drug: Prazaxa

Study type: Observational

Funder types: Industry

Identifiers

NCT01491178

1160.130

Details and patient eligibility

About

To investigate the safety and efficacy of long-term use of Prazaxa® Capsules in patients with nonvalvular atrial fibrillation for preventing the occurrence of ischemic stroke or systemic embolism (SEE).

Enrollment: 6,772 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with nonvalvular atrial fibrillation who have never received Prazaxa Capsules for preventing the occurrence of ischemic stroke and systemic embolism will be included.

Exclusion criteria

• None

Trial design

6,772 participants in 1 patient group

Patients with NVAF

Treatment:

Drug: Prazaxa